抗VEGF治疗新生血管性年龄相关性黄斑变性的安全性与疗效:美国眼科学会报告
结论认为玻璃体腔注射抗VEGF药物治疗新生血管性AMD在2年数据范围内安全有效,需进一步研究长期安全性和比较疗效。
要点
- 玻璃体腔注射雷珠单抗、阿柏西普和贝伐珠单抗治疗新生血管性AMD有I级证据支持。
- 抗VEGF治疗在2年数据覆盖期内安全有效。
- 雷珠单抗和贝伐珠单抗有≥5年随访数据,但存在随访不完整的偏倚。
核心结论
- 玻璃体腔注射抗VEGF治疗新生血管性AMD在2年数据范围内安全有效。
- 需进一步研究评估这些药物的长期安全性和比较疗效。
研究设计与样本
- 美国眼科学会眼科技术评估委员会视网膜/玻璃体专家组完成的文献综述。
- 检索PubMed和Cochrane图书馆数据库,末次检索时间为2017年2月,无日期限制,限英文文献。
- 合并检索共获得191条引文,其中28项临床试验被选为临床相关并由专家组全文审阅。
- 方法学家对每项研究分配证据等级,最终仅纳入I级证据研究。
主要发现
- 8项研究提供II级证据,4项研究提供III级证据,但本评估仅纳入I级证据研究。
- 雷珠单抗和贝伐珠单抗有≥5年疗效随访数据,但受随访不完整偏倚影响。
关键数值与推荐
- 抗VEGF治疗安全有效的数据覆盖期为2年。
临床怎么用
- 临床可依据I级证据对新生血管性AMD患者使用玻璃体腔注射雷珠单抗、阿柏西普或贝伐珠单抗。
- 应知晓2年数据支持安全有效,长期安全性和比较疗效尚待进一步研究。
局限性
- 长期随访数据(≥5年)存在随访不完整的偏倚。
- 仅纳入I级证据研究,未纳入II级和III级证据研究。
- 文献检索末次时间为2017年2月,未涵盖此后发表的研究。
- 需进一步研究评估长期安全性和比较疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To review the evidence on the safety and efficacy of anti-vascular endothelial growth factor (VEGF) therapies for the treatment of neovascular age-related macular degeneration (AMD). METHODS: A literature search of the PubMed and Cochrane Library databases was last conducted in February 2017; there were no date restrictions, and the search was limited to studies published in English. The combined searches yielded 191 citations, 28 of which were selected because they were clinical trials and were deemed clinically relevant for the Ophthalmic Technology Assessment Committee Retina/Vitreous Panel to review in full. The panel methodologist then assigned a level of evidence rating to each study. RESULTS: Sixteen of the 28 citations provided level I evidence supporting the use of anti-VEGF agents for neovascular AMD, including intravitreal ranibizumab, aflibercept, and bevacizumab. Eight studies reviewed provided level II evidence, and 4 studies provided level III evidence, but only the level I studies are included in this assessment. There are long-term follow-up data on the efficacy of ranibizumab and bevacizumab (≥5 years), but these data are subject to the bias of incomplete follow-up. CONCLUSIONS: Review of the literature indicates that intravitreal injection of anti-VEGF therapy is safe and effective for neovascular AMD over 2 years, the period for which data are available. Further research is needed to evaluate the long-term safety and comparative efficacy of these agents.
引用
- Bakri SJ, Thorne JE, Ho AC, et al. Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration: A Report by the American Academy of Ophthalmology. Ophthalmology. 2018. PMID: 30077616. doi:10.1016/j.ophtha.2018.07.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。